Sipai Health Technology Co (HKSE:00314) Risk Assessment

View and export this data going back to 2022. Start your Free Trial

What is Sipai Health Technology Co Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Sipai Health Technology Co is: No Data: Cannot be evaluated.

Competitive Comparison of Sipai Health Technology Co's Risk Assessment

For the Medical Distribution subindustry, Sipai Health Technology Co's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sipai Health Technology Co's Risk Assessment Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Sipai Health Technology Co's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Sipai Health Technology Co's Risk Assessment falls into.

Sipai Health Technology Co (HKSE:00314) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Sipai Health Technology Co Risk Assessment Related Terms

Thank you for viewing the detailed overview of Sipai Health Technology Co's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Sipai Health Technology Co (HKSE:00314) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Sipai Health Technology Co Ltd (HKSE:00314) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

AX1:Germany

Address

No. 1888, Caoyang Road, 7/F, Building 3, Xingguangyao Plaza, Putuo District, Shanghai, CHN

Website

https://www.medbankshealthtech.com

Sipai Health Technology Co Ltd is a medical technology and health management company in China. It has three reportable operating segments: Specialty Pharmacy Business - operation and distribution of specialty pharmacy stores and pharmaceutical products; Physician Research Assistance Business - offering pharmaceutical companies and other clinical trial institutions site management organization services; Health Insurance Services Business - rendering insurance brokerage services to insurance companies. The company generates key revenue from Specialty Pharmacy Business. Almost all of the company's revenues were derived from operations in the PRC.

Executives

Chang Jimmy Ching-hsin	2201 Interest of corporation controlled by you
Jeneration Group Limited	2201 Interest of corporation controlled by you
Leung Catherine Ho Yan	2202 Interest of your spouse
Purple Panther	2201 Interest of corporation controlled by you
Ma Xuguang	2501 Other
Li Ji	2501 Other
Wise Approach Investments Limited	2101 Beneficial owner
Ark Trust (hong Kong) Limited	2301 Trustee
Jpmorgan Chase & Co.	2502 Approved lending agent
Lucky Seven Healthcare Co., Ltd.	2101 Beneficial owner
Simul International Holdings Limited	2201 Interest of corporation controlled by you
Oriental Power Holdings Limited
Nasturtium Investment Limited
Tencent Mobility Limited
Tencent Holdings Limited

Sipai Health Technology Co (HKSE:00314) Headlines

No Headlines